Endocrine Treatment with 2 Years of Tamoxifen versus 2 Years of Exemestane in Postmenopausal Patients with High-Risk Early Breast Cancer and Persisting Circulating Tumor Cells - First Results of the SUCCESS C Endocrine Treatment Sub-Study

Background: Optimal choice and sequence of endocrine treatment following adjuvant chemotherapy in postmenopausal early breast cancer patients are still under discussion and treatment stratification factors are missing. Patients and Methods: Postmenopausal women with HER2-negative, hormone receptor-positive tumors and persisting circulating tumor cells (CTCs; assessed using the FDA-approved CellSearch® System, Janssen Diagnostics, LLC) after chemotherapy were randomized to 2 years of tamoxifen followed by 3 years of exemestane (tamoxifen-exemestane group, n = 54) or 5 years of exemestane (exemestane-only group, n = 54). CTCs were again assessed after the first 2 years of endocrine treatment. In addition, safety data were compared between the 2 groups. Results: The 2 groups were well-balanced with regard to baseline characteristics. The CTC clearance rate after 2 years was 89% in the exemestane-only group and 97% in the tamoxifen-exemestane group (exact Fisher test, p = 0.36). The safety profile showed good tolerability with few grade 3 or 4 adverse events in both groups. Conclusion: The similar CTC clearance rate after 2 years of endocrine therapy with exemestane or tamoxifen, and the safety profiles obtained may indicate comparable efficacy and tolerability of both endocrine treatment regimens. However, these results have to be confirmed by final survival and safety analysis.

[1]  M. Höistad,et al.  Aromatase inhibitors alone or sequentially combined with tamoxifen in postmenopausal early breast cancer compared with tamoxifen or placebo - Meta-analyses on efficacy and adverse events based on randomized clinical trials. , 2016, Breast.

[2]  M. Beckmann,et al.  Abstract S2-03: Persistence of circulating tumor cells in high risk early breast cancer patients during follow-up care suggests poor prognosis – Results from the adjuvant SUCCESS A trial , 2016 .

[3]  Tanja Fehm,et al.  Pooled Analysis of the Prognostic Relevance of Circulating Tumor Cells in Primary Breast Cancer , 2016, Clinical Cancer Research.

[4]  A. Eisen,et al.  Adjuvant endocrine therapy for early breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline. , 2015, Current oncology.

[5]  Tanja Fehm,et al.  Circulating Tumor Cells Predict Survival in Early Average-to-High Risk Breast Cancer Patients , 2014, Journal of the National Cancer Institute.

[6]  H. Kuerer,et al.  Circulating tumour cells in non-metastatic breast cancer: a prospective study. , 2012, The Lancet. Oncology.

[7]  K. Pantel,et al.  Clinical relevance and biology of circulating tumor cells , 2011, Breast Cancer Research.

[8]  Patrick Neven,et al.  Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up. , 2011, The Lancet. Oncology.

[9]  A. Ocaña,et al.  Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. , 2011, Journal of the National Cancer Institute.

[10]  Hein Putter,et al.  Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial , 2011, The Lancet.

[11]  M. Beckmann,et al.  The German SUCCESS C Study – The First European Lifestyle Study on Breast Cancer , 2010, Breast Care.

[12]  W. Janni,et al.  Adjuvant aromatase inhibitor therapy: outcomes and safety. , 2010, Cancer treatment reviews.

[13]  A. Giobbie-Hurder,et al.  Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. , 2009, The New England journal of medicine.

[14]  Anne Vincent-Salomon,et al.  Circulating Tumor Cell Detection Predicts Early Metastatic Relapse After Neoadjuvant Chemotherapy in Large Operable and Locally Advanced Breast Cancer in a Phase II Randomized Trial , 2008, Clinical Cancer Research.

[15]  Brigitte Rack,et al.  Detection of Circulating Tumor Cells in Peripheral Blood of Patients with Metastatic Breast Cancer: A Validation Study of the CellSearch System , 2007, Clinical Cancer Research.

[16]  T. Fehm,et al.  Circulating tumor cells in breast cancer--current status and perspectives. , 2016, Critical reviews in oncology/hematology.

[17]  Leon W M M Terstappen,et al.  Circulating tumor cells before and during follow-up after breast cancer surgery. , 2015, International journal of oncology.

[18]  I. Ellis,et al.  Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. , 2002, Histopathology.